Angiogenesis Inhibitors
- Name
- Angiogenesis Inhibitors
- Accession Number
- DBCAT000222
- Description
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
- Drugs
Drug Drug Description Bevacizumab A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer. Lenalidomide A thalidomide derivative used to treat multiple myeloma and anemia in low to intermediate risk myelodysplastic syndrome. Thalidomide A medication used to treat cancers, particularly newly diagnosed multiple myeloma, and erythema nodosum leprosum. Sunitinib A receptor tyrosine kinase inhibitor and chemotherapeutic agent used for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Ranibizumab A recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema. Fumagillin Not Available Resveratrol Being investigated for the treatment of Herpes labialis infections (cold sores). Halofuginone For the treatment of scleroderma, cancer, and restenosis. Anecortave acetate Investigated for use/treatment in glaucoma and macular degeneration. Endostatin Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy. Semaxanib Investigated for use/treatment in colorectal cancer and lung cancer. Squalamine Investigated for use/treatment in ovarian cancer, lung cancer, and macular degeneration. Pazopanib An antineoplastic agent used in the treatment of advanced renal cell cancer and advanced soft tissue sarcoma in patients with prior chemotherapy. Pomalidomide A thalidomide analogue used in combination with dexamethasone to treat patients with multiple myeloma. Roquinimex Roquinimex is investigated to be used as a treatment of a number of cancers and autoimmune conditions. As well, roquinimex is researched to be used as adjuvant therapy after bone... Trebananib Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon... Anecortave Anecortave is under investigation in clinical trial NCT00691717 (Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension). TNP-470 O-(chloroacetylcarbamoyl)fumagillol (TNP-470) has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, and Pancreatic Neoplasms. Volociximab Investigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer. Endostar Endostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer. Beloranib Beloranib has been used in trials studying the treatment of Obesity, Over-weight, Type 2 Diabetes, Craniopharyngioma, and Hypothalamic Injury, among others. Brolucizumab An anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration. Aflibercept A vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy, and metastatic colorectal cancer Xanthohumol Xanthohumol is under investigation in clinical trial NCT01367431 (Xanthohumol and Metabolic Syndrome). Edodekin alfa Edodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or... Faricimab An IgG1-derived bispecific antibody against VEGF-A and Ang-2 for the treatment of age-related macular degeneration and diabetic macular edema. Ammonium tetrathiomolybdate Not Annotated Ramucirumab An antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply. - Drugs & Drug Targets